SECTIONS
ET APPS
LIVE BLOG
Economic Times | 04 Jun, 2020 | 08.25AM IST
Coronavirus Live Updates: HCQ ineffective against COVID-19
An experiment involving 821 people across the United States and Canada showed hydroxychloroquine did not work significantly better than a placebo, even as Presidents Trump and Bolsonaro adamantly advocate its use.
!1 New UpdateClick here for latest updates
Germany's cases rise by 394
Total cases stood at 1,82,764, while the death toll rose by 30 to 8,581.
From Punjab
As of 3rd June, Punjab has a total of 300 active cases out of 2,376 patients that have tested positive so far. Yest… https://t.co/tIF9tWPFTz
— Capt.Amarinder Singh (@capt_amarinder) 1591237800000S.Korea reports 39 fresh cases
Pompeo speaks to foreign ministers of various countries
US Secretary of State Mike Pompeo has spoken to the foreign ministers of Australia, Brazil, India, Israel and South Korea on the coronavirus situation.
Trainspotting:
Indian Railways operationalizes 4197 “Shramik Special” trains till 3rd June, 2020 (0900hrs) across the country. Tra… https://t.co/hMoQeyWm3Y
— Ministry of Railways (@RailMinIndia) 1591202600000Mexico reports new one-day high of 1,092 deaths
The number of new confirmed cases rose by 3,912, pushing Mexico's total for the pandemic into six figures, at 1,01,238.
Brazil reports record 1,349 deaths
Germany's government agrees on a €130 billion package
Under the wide-ranging measures outlined in a 15-page document, value-added tax will be temporarily slashed, families will receive €300 for each child, while those who purchase electric cars will see a government rebate doubled to €6,000.
France's death toll crosses 29,000
France registered 81 deaths to take the toll to 29,021.
Hydroxychloroquine ineffective at preventing COVID-19
- Researchers enrolled adults who had come into contact with someone who had a confirmed case of COVID-19 for more than 10 minutes at a distance of six feet (about two meters) or less.
- The majority of them - 719 - were deemed to have had "high-risk" exposure because they wore neither a face mask nor an eye shield at the time.
- All participants were randomly assigned to receive either hydroxychloroquine - which is certified for use against malaria, rheumatoid arthritis and lupus - or a placebo, within four days.
- The researchers then looked at how many patients went on to develop COVID-19 over the next two weeks, which was confirmed either by a laboratory test or by clinical signs.
- They found that 49 of the 414 given the medicine got the disease caused by the coronavirus, compared to 58 of the 407 on the placebo.
- This translates to 11.83 percent on the drug were infected, versus 14.25 percent on the placebo.
- The absolute difference of about 2.4 percentage points in favor of the medicine was not considered statistically significant given the sample size, meaning it could have occurred because of chance.
- Side effects were more common with hydroxychloroquine than with the placebo - 40.1 percent versus 16.8 percent - but no serious adverse reactions were reported.
Brazil to test British vaccine
China reports five new cases
Of these cases, four of the patients were asymptomatic.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service
^Go to Top
